XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
LULUTOX Detox Tea in Consumer Coverage as Website Update Introduces More Transparency in Herbal Digestive Supplement Information
Relapse Risk Increases During the Holidays; Desert Hope Treatment Center Urges Early Support
Profound Medical Corp. Announces Upsize of Private Placement
ImmuCell Announces Strategic Focus on First Defense® After Receiving an FDA Incomplete Letter for Re-Tain®
VYN201 demonstrated statistically significant improvement in treatment response for both endpoints at 1mg/kg and 10mg/kg dosesVYN201 also demonstrated numerically superior results...
All enrolled patients were 2nd line metastatic non-small cell lung carcinoma (NSCLC) patients that had confirmed progressive disease after prior...
Highlights: 10 subjects in cohort four intravenously dosed; RECCE® 327 at 1,000mg, indicating to be safe and well-tolerated Independent Safety...
HOUSTON, March 30, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to...
- First therapeutic candidate for the treatment of SSc-ILD targeting both key fibrotic and inflammatory pathways - - ATHENA-SSc-ILD Phase...
Highlights Focused as a pure-play drug discovery and development biotechnology companyPrimary work on the discovery of small molecule therapeutics to...
BOCA RATON, Fla., March 30, 2022 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF),...
Confirmatory trial’s completion is expected in an accelerated timeline of four years with patient screening to start in MayMultiple strategies...
Phase 1/2 TCR-T Library trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications; first patient consented and...
- Full Year 2021 Total Revenue Growth of 48%, and 11% in Core Business Segments, Exceeds Guidance - Focus on...
Phase 2 trial with optimized formulation in wet AMD expected to start in fourth quarter of 2022Phase 1 trial in...
LEAMINGTON, Ontario, March 30, 2022 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray Brands” or the “Company”) (Nasdaq | TSX: TLRY),...
- Well capitalized from $52 million IPO and $169 million in grant funding -- Established clinical program in Alzheimer’s disease...
SOUTH SAN FRANCISCO, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on...
EMERYVILLE, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next...
RP1 combined with Opdivo® (nivolumab) continues to demonstrate deep and durable responses in patients with melanoma and non-melanoma skin cancers...
Libmeldy European launch momentum building with multiple MLD patients treated and strong recognition of value proposition; U.S. BLA filing of...
Company to host a Conference Call & Webcast at 8:00 a.m. ETCHESTERBROOK, Pa., March 30, 2022 (GLOBE NEWSWIRE) -- Trevena,...
NERx innovations make leaps towards breast and lung cancer treatmentINDIANAPOLIS, March 30, 2022 (GLOBE NEWSWIRE) -- NERx Biosciences, an oncology...
MALVERN, Pa., March 30, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing...
